Aquestive Therapeutics (AQST) Interest Expenses (2017 - 2026)

Aquestive Therapeutics' Interest Expenses history runs 10 years deep, the most recent figure standing at $7.4 million for Q1 2026.

• On a quarterly basis, Interest Expenses fell 14.82% year-over-year to $7.4 million in Q1 2026; TTM through Mar 2026 was $7.4 million, a 14.82% decrease from a year earlier, with the FY2025 full-year figure at $113.2 million, up 19.69% from the prior year.
• Interest Expenses grew to $7.4 million in Q1 2026 per AQST's latest filing, from -$2.2 million in the prior quarter.
• Across five years, Interest Expenses topped out at $11.0 million in Q1 2023 and bottomed at -$7.5 million in Q4 2024.
• The 5-year median for Interest Expenses is $4.5 million (2023), against an average of $5.0 million.
• Across the five-year window, Interest Expenses jumped 240.44% in 2023 and tumbled 522.2% in 2024, its largest moves.
• Year by year, Interest Expenses stood at $1.6 million in 2022, then gained by 7.58% to $1.8 million in 2023, then tumbled by 522.2% to -$7.5 million in 2024, then surged by 70.06% to -$2.2 million in 2025, then surged by 431.19% to $7.4 million in 2026.
• Per Business Quant, the three latest AQST Interest Expenses figures stand at $7.4 million (Q1 2026), -$2.2 million (Q4 2025), and $3.0 million (Q3 2025).